Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.70 |
| ▸ | DPYD | Q12882 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL3972004 | 0.89 | ATAD2 (0.56) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL27971877 | 0.86 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL211721 | 0.85 | ATAD2 (0.70) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL5235 | 0.84 | — | — | |
| Thymine SCHEMBL15323914 | 0.84 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL17201833 | 0.84 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL750450 | 0.84 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL29669526 | 0.84 | — | — | |
| Thymine SCHEMBL4725364 | 0.84 | ATAD2 (0.68) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL7902560 | 0.82 | ATAD2 (0.86) | ATAD2DPYDMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170851-B1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | claimed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | claimed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | claimed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | claimed |
| EP-2170851-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2010-04-07 | — | — | EP | claimed |
| EP-2167476-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | Korea Research Institute Of Chemical Technology (KR) | 2010-03-31 | — | — | EP | claimed |
| US-7615542-B2 | Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-11-10 | — | — | US | claimed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | claimed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | claimed |
| WO-2009008989-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| WO-2009005693-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-20050209196-A1 | Dioxolane thymine and combinations for use against 3tc/azt resistant strains of hiv | CHU CHUNG K | 2005-09-22 | — | — | US | claimed |
| EP-1569659-A2 | DIOXOLANE THYMINE AND COMBINATIONS FOR USE AGAINST 3TC/ AZT RESISTANT STRAINS OF HIV | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004052296-A2 | DIOXOLANE THYMINE AND COMBINATIONS FOR USE AGAINST 3TC/ AZT RESISTANT STRAINS OF HIV | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| EP-0562009-A1 | ENANTIOMERICALLY PURE $g(b)-D-(-)-DIOXOLANE-NUCLEOSIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010497-A1 | ENANTIOMERICALLY PURE β-D-(-)-DIOXOLANE-NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | ATAD2 4737/4885DPYD 1084/4885MAPT 1880/4885 |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | ATAD2 2547/4885DPYD 64/4885MAPT 437/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | ATAD2 2547/4885DPYD 64/4885MAPT 437/4885 |
| US-20050209196-A1 | Dioxolane thymine and combinations for use against 3tc/azt resistant strains of hiv | TYMP, DTYMK, TK1 | ATAD2 1873/4885DPYD 6/4885MAPT 2980/4885 |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | ATAD2 2547/4885DPYD 64/4885MAPT 437/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | ATAD2 1411/4885DPYD 4364/4885MAPT 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.